Dianthus Therapeutics, Inc.

Dianthus Therapeutics (NASDAQ:DNTH) Given "Buy" Rating at HC Wainwright
MarketBeat · 20 Oct 2026
451,597 Dianthus Therapeutics, Inc. $DNTH Shares Purchased by Assenagon Asset Management S.A.
MarketBeat · 17 Oct 2026
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
The Manila Times · 13 Oct 2026
Dianthus Therapeutics named among Fortune's 202...
Pluang · 13 Oct 2026
Dianthus Therapeutics (DNTH) Files A Large Equity Offering, Is The Upside Already Priced In?
Simply Wall Street · 25 Sep 2026
Bank of America Corp DE Takes Position in Dianthus Therapeutics, Inc. $DNTH
MarketBeat · 24 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.